ATE511656T1 - Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis - Google Patents

Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis

Info

Publication number
ATE511656T1
ATE511656T1 AT07802468T AT07802468T ATE511656T1 AT E511656 T1 ATE511656 T1 AT E511656T1 AT 07802468 T AT07802468 T AT 07802468T AT 07802468 T AT07802468 T AT 07802468T AT E511656 T1 ATE511656 T1 AT E511656T1
Authority
AT
Austria
Prior art keywords
gdf
subject
present
risk assessment
procedures based
Prior art date
Application number
AT07802468T
Other languages
English (en)
Inventor
Kai Christoph Wollert
Tibor Kempf
Lars Wallentin
Helmut Drexler
Original Assignee
Hannover Med Hochschule
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06118464A external-priority patent/EP1884777A1/de
Application filed by Hannover Med Hochschule filed Critical Hannover Med Hochschule
Application granted granted Critical
Publication of ATE511656T1 publication Critical patent/ATE511656T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
AT07802468T 2006-08-04 2007-08-02 Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis ATE511656T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06118464A EP1884777A1 (de) 2006-08-04 2006-08-04 Mittel und Verfahren zur Risikobewertung von Herzeingriffen auf GDF-15-Basis
EP06121413 2006-09-28
EP07108854 2007-05-24
PCT/EP2007/058007 WO2008015254A2 (en) 2006-08-04 2007-08-02 Means and methods for assessing the risk of cardiac interventions based on gdf-15

Publications (1)

Publication Number Publication Date
ATE511656T1 true ATE511656T1 (de) 2011-06-15

Family

ID=38596870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07802468T ATE511656T1 (de) 2006-08-04 2007-08-02 Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis

Country Status (11)

Country Link
US (3) US8951742B2 (de)
EP (2) EP2315034A3 (de)
JP (1) JP5309026B2 (de)
KR (1) KR101245877B1 (de)
CN (1) CN106018820B (de)
AT (1) ATE511656T1 (de)
AU (1) AU2007280413B2 (de)
BR (1) BRPI0715126B8 (de)
CA (1) CA2660691C (de)
MX (1) MX2009000914A (de)
WO (1) WO2008015254A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE537454T1 (de) * 2007-05-24 2011-12-15 Hoffmann La Roche Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
WO2009027514A1 (en) * 2007-08-30 2009-03-05 Roche Diagnostics Gmbh Means and methods for the discrimination of gdf-15 elevation related or unrelated to cardiac disorders
WO2009047283A2 (en) * 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
EP2103943A1 (de) 2008-03-20 2009-09-23 F. Hoffman-la Roche AG GDF-15 zur Beurteilung eines kardiovaskulären Risikos hinsichtlich Verabreichung von Entzündungshemmern
CA2722485C (en) * 2008-04-30 2018-02-13 F. Hoffmann-La Roche Ag Use of sfrp-3 in the assessment of heart failure
EP2318844A1 (de) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz
US8200466B2 (en) 2008-07-21 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Method for tuning patient-specific cardiovascular simulations
US9405886B2 (en) 2009-03-17 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Method for determining cardiovascular information
ES2647461T3 (es) * 2009-12-18 2017-12-21 F. Hoffmann-La Roche Ag GDF-15 y/o troponina T para predecir insuficiencia renal en pacientes con cirugía cardíaca
EP2388594A1 (de) * 2010-05-17 2011-11-23 Roche Diagnostics GmbH Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung
US8315812B2 (en) 2010-08-12 2012-11-20 Heartflow, Inc. Method and system for patient-specific modeling of blood flow
CN108387744A (zh) * 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
WO2012074888A2 (en) * 2010-11-29 2012-06-07 Alere San Diego, Inc. Methods and compositions for diagnosis and risk prediction in heart failure
WO2013022760A1 (en) * 2011-08-05 2013-02-14 Alere San Diego, Inc. Methods and compositions for monitoring heart failure
EP2769227B1 (de) 2011-10-17 2016-07-27 Roche Diagnostics GmbH Auf troponin und bnp basierende diagnose von risikopatienten und ursache eines schlaganfalls
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
CA2873896A1 (en) 2012-05-18 2013-11-21 Critical Care Diagnostics, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
US9002769B2 (en) * 2012-07-03 2015-04-07 Siemens Aktiengesellschaft Method and system for supporting a clinical diagnosis
EP2730923A1 (de) 2012-11-09 2014-05-14 Roche Diagniostics GmbH NTproBNP- und cTnT-basierte Therapieanleitung bei Herzversagen
CA2893639C (en) 2012-12-04 2021-01-05 F. Hoffmann-La Roche Ag Biomarkers in the selection of therapy of heart failure
AU2013364133B2 (en) 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
DE102013100367A1 (de) 2013-01-15 2014-07-17 Sick Ag Entfernungsmessender optoelektronischer Sensor und Verfahren zur Abstandsbestimmung von Objekten
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2843414B1 (de) 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker zur statinbehandlungsstratifikation bei herzversagen
EP2899544B1 (de) 2014-01-28 2018-12-26 Roche Diagnostics GmbH Biomarker zur Risikobewertung und Behandlungsüberwachung bei Patienten mit Herzinsuffizienz, die auf Basis des natriuretischen Peptids des Typs B behandelt werden
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
EA035581B1 (ru) 2014-07-30 2020-07-10 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы применения для лечения метаболических расстройств
DK3212226T3 (da) 2014-10-31 2020-06-15 Ngm Biopharmaceuticals Inc Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
WO2017150314A1 (ja) 2016-02-29 2017-09-08 公立大学法人横浜市立大学 去勢抵抗性前立腺癌を検出する方法及び検出試薬
TWI897070B (zh) 2016-03-31 2025-09-11 美商恩格姆生物製藥公司 結合蛋白質及其使用方法
US10279712B2 (en) 2016-07-14 2019-05-07 Bae Industries, Inc. Rear row seat latch assembly with power and manual driven variants
US10195962B2 (en) 2016-07-14 2019-02-05 Bae Industries, Inc. Power seat assembly with spring loaded seatback dump and motor driven design rewind and reset functionality
JP7127422B2 (ja) 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
EP3943946A1 (de) 2020-07-20 2022-01-26 F. Hoffmann-La Roche AG Gdf-15 zur vorhersage der erkrankungsschwere eines patienten mit covid-19
EP3961219A3 (de) * 2020-08-31 2022-06-22 The Chinese University Of Hong Kong Verwendung von gdf-15 bei der diagnose und behandlung von gebrechlichkeit und zuständen, die mit veränderter physiologischer reserve, physischer fitness und trainingsfähigkeit verbunden sind
GB2621544A (en) * 2022-07-07 2024-02-21 Biohabit Ltd Methods of detecting a disease or condition

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
PT808172E (pt) * 1995-02-10 2003-11-28 Searle & Co Combinacao de inibidor da enzima de conversao da angiotensina e de antagonista de aldosterona para o tratamento de hipertrofia ventricular
US6248869B1 (en) * 1997-05-29 2001-06-19 Medical Analysis Systems, Inc. Troponin I forms and use of the same
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
PT1179067E (pt) * 1999-05-17 2007-01-31 Biopharm G Biotechnolo Entwi V Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta
SE0000363L (sv) * 2000-02-04 2001-08-05 Zoucas Kirurgkonsult Ab Belagd medicinsk anordning
ES2346918T3 (es) 2000-04-20 2010-10-21 St Vincent's Hospital Sydney Limited Ensayo para diagnostico que involucra a la citoquina-1 (mic-1) inhibidora de macrofagos.
CA2432991A1 (en) 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
EP1322957B1 (de) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
EP1393074A1 (de) * 2001-06-05 2004-03-03 Genomics, Ltd. Zusammenfassungen und verfahren zur bestimmung von mit kardiovaskulären erkrankungen assozieerten biomarker
EP1450863A4 (de) * 2001-11-07 2009-01-07 Imcor Pharmaceutical Company Verfahren für die bilddarstellung von gefässen mit nanoteilchenförmigen kontrastmitteln
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20040096919A1 (en) * 2002-11-18 2004-05-20 Michelle Davey Polyclonal-monoclonal ELISA assay for detecting N-terminus proBNP
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040215240A1 (en) * 2003-04-11 2004-10-28 Lovett Eric G. Reconfigurable subcutaneous cardiac device
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
ATE403157T1 (de) * 2004-03-15 2008-08-15 Hoffmann La Roche Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
PL2441466T3 (pl) * 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
WO2005124364A1 (en) * 2004-06-15 2005-12-29 F. Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication

Also Published As

Publication number Publication date
US11199552B2 (en) 2021-12-14
AU2007280413B2 (en) 2010-08-26
EP2315034A2 (de) 2011-04-27
WO2008015254A3 (en) 2008-06-05
KR101245877B1 (ko) 2013-03-20
CN106018820A (zh) 2016-10-12
JP5309026B2 (ja) 2013-10-09
WO2008015254A2 (en) 2008-02-07
KR20090047451A (ko) 2009-05-12
CA2660691C (en) 2020-01-14
AU2007280413A1 (en) 2008-02-07
US20200081020A1 (en) 2020-03-12
BRPI0715126B8 (pt) 2021-07-27
CA2660691A1 (en) 2008-02-07
CN106018820B (zh) 2018-04-27
EP2315034A3 (de) 2011-08-17
EP2047275B1 (de) 2011-06-01
BRPI0715126A2 (pt) 2013-06-04
BRPI0715126B1 (pt) 2018-05-22
HK1136627A1 (zh) 2010-07-02
US20110065204A1 (en) 2011-03-17
MX2009000914A (es) 2009-06-18
EP2047275A2 (de) 2009-04-15
US20150362511A1 (en) 2015-12-17
JP2009545735A (ja) 2009-12-24
US8951742B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
ATE511656T1 (de) Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
ATE489482T1 (de) Verfahren zur herstellung von hybridsubstraten mit dna und antikörpern sowie verwendungen davon
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
EP4099596C0 (de) Verfahren zur gewinnung von ressourcenbereichsinformationen für phich und verfahren zum empfangen von pdcch
DE602005021336D1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
ATE535805T1 (de) Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
ATE545712T1 (de) Verfahren mit verwendung von poren
AT505105A3 (de) Verfahren zur beurteilung der fahrbarkeit von fahrzeugen
DE602007013524D1 (de) Erkennung und vorhersage von frühgeburten
ATE433124T1 (de) System und verfahren zum analysieren von radarinformationen
ATE470862T1 (de) Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten
ATE524561T1 (de) Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
ATE529533T1 (de) Verfahren zum nachweis von analyten in einer probe
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE502004005365D1 (de) Verfahren zur quantitativen Messung von Ablagerung auf festen Oberflächen
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
DE602006008581D1 (de) Verfahren zur bestimmung von montagebedingungen, vorrichtung zur bestimmung von montagebedingungen und montagevorrichtung
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
ATE551605T1 (de) Verfahren und vorrichtungen zur erkennung von biofilmen
ATE515574T1 (de) Verwendung von spla2-aktivität zur diagnose von herz-kreislauf-ereignissen
EP1861706A4 (de) Vorrichtungen und verfahren für analyttests mit eingebauter ergebnismitteilung unter verwendung erkennbarer symbole
ATE529745T1 (de) Verfahren zur bewertung des hautempfindlichkeitsniveaus durch verwendung von mit plattenepithelkarzinom zusammenhängendem antigen als indikation
DE502005002108D1 (de) Verfahren zur funktionalisierung von biosensor-chips
ATE547161T1 (de) Verfahren zur quantitativen bestimmung von poloxameren
DE112006001519A5 (de) Verfahren und Einrichtung zur Ermittlung von Informationen über ein Tier und/oder Tiermilch

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2047275

Country of ref document: EP